Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
January 15, 2021 at 07:17 AM EST
ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
